{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:37:29Z","timestamp":1789612649740,"version":"build-2803163510"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Despite public health concerns that cannabis legalization may increase the number of cases of schizophrenia caused by cannabis, there is limited evidence on this topic.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine changes in the population-attributable risk fraction (PARF) for cannabis use disorder (CUD) associated with schizophrenia after liberalization of medical cannabis and legalization of nonmedical cannabis in Canada.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This population-based cohort study was conducted in Ontario, Canada, from January 1, 2006, to December 31, 2022, among 13\u202f588\u202f681 people aged 14 to 65 years without a history of schizophrenia.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n \n Diagnosis of CUD in the emergency department or hospital setting (\n International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Canada<\/jats:italic>\n [\n ICD-10-CA<\/jats:italic>\n ] codes F12x and T40.7).\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n \n Changes in the PARF for CUD associated with schizophrenia (\n ICD-10-CA<\/jats:italic>\n codes F20x and F25x and\n Diagnostic and Statistical Manual of Mental Disorders<\/jats:italic>\n [Fourth Edition] [\n DSM-IV<\/jats:italic>\n ] code 295x) over 3 policy periods: prelegalization (January 2006 to November 2015), liberalization of medical and nonmedical cannabis (December 2015 to September 2018), and legalization of nonmedical cannabis (October 2018 to December 2022). A secondary outcome was diagnosis of psychosis not otherwise specified (NOS) (\n ICD-10-CA<\/jats:italic>\n code F29x and\n DSM-IV<\/jats:italic>\n code 298x). Segmented linear regression was used to examine changes after the liberalization of medical cannabis in 2015 and the legalization of nonmedical cannabis in 2018.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The study included 13\u202f588\u202f681 individuals (mean [SD] age, 39.3 [16.1] years; 6\u202f804\u202f906 males [50.1%]), of whom 118\u202f650 (0.9%) had CUD. A total of 91\u202f106 individuals (0.7%) developed schizophrenia (80\u202f523 of 13\u202f470\u202f031 [0.6%] in the general population without CUD vs 10\u202f583 of 118\u202f650 [8.9%] with CUD). The PARF for CUD associated with schizophrenia almost tripled from 3.7% (95% CI, 2.7%-4.7%) during the prelegalization period to 10.3% (95% CI, 8.9%-11.7%) during the legalization period. The PARF in the postlegalization period ranged from 18.9% (95% CI, 16.8%-21.0%) among males aged 19 to 24 years to 1.8% (95% CI, 1.1%-2.6%) among females aged 45 to 65 years. The annual incidence of schizophrenia was stable over time, while the incidence of psychosis NOS increased from 30.0 to 55.1 per 100\u202f000 individuals (83.7%) in the postlegalization period relative to the prelegalization period. The PARF for CUD associated with schizophrenia increased steadily over the study with no accelerations after cannabis policy changes, while increases in the PARF for CUD associated with psychosis NOS accelerated after medical cannabis liberalization.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of individuals aged 14 to 65 years in Ontario, Canada, the proportion of incident cases of schizophrenia associated with CUD almost tripled during a period of substantial liberalization of cannabis policy. Ongoing research is indicated to understand the long-term associations of cannabis policy with the prevalence of psychotic disorders.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.57868","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T11:07:32Z","timestamp":1738667252000},"page":"e2457868","source":"Crossref","is-referenced-by-count":52,"title":["Changes in Incident Schizophrenia Diagnoses Associated With Cannabis Use Disorder After Cannabis Legalization"],"prefix":"10.1001","volume":"8","author":[{"given":"Daniel T.","family":"Myran","sequence":"first","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"Department of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"ICES uOttawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pugliese","sequence":"additional","affiliation":[{"name":"ICES uOttawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndsay D.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"Bruy\u00e8re Health Research Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Solmi","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"Department of Psychiatry, University of Ottawa, Ottawa, Ontario, Canada."},{"name":"Department of Mental Health, The Ottawa Hospital, Ottawa, Ontario, Canada."},{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Department of Child and Adolescent Psychiatry, Charit\u00e9 Universit\u00e4tsmedizin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly K.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada"},{"name":"Department of Psychiatry, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada"},{"name":"ICES Western, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jess G.","family":"Fiedorowicz","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"Department of Psychiatry, University of Ottawa, Ottawa, Ontario, Canada."},{"name":"Department of Mental Health, The Ottawa Hospital, Ottawa, Ontario, Canada."},{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Finkelstein","sequence":"additional","affiliation":[{"name":"Division of Pediatric Emergency Medicine, Hospital for Sick Children, Toronto, Ontario, Canada"},{"name":"Division of Clinical Pharmacology and Toxicology, Hospital for Sick Children, Toronto, Ontario, Canada"},{"name":"Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Manuel","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"Department of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Bruy\u00e8re Health Research Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Taljaard","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Webber","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"ICES uOttawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"Bruy\u00e8re Health Research Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tanuseputro","sequence":"additional","affiliation":[{"name":"ICES uOttawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"Bruy\u00e8re Health Research Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"issue":"5","key":"zoi241621r1","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/mp.2016.252","article-title":"Cannabis use and risk of schizophrenia: a mendelian randomization study.","volume":"23","author":"Vaucher","year":"2018","journal-title":"Mol Psychiatry"},{"issue":"8","key":"zoi241621r2","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1038\/s41380-022-01586-8","article-title":"Global population attributable fraction of potentially modifiable risk factors for mental disorders: a meta-umbrella systematic review.","volume":"27","author":"Dragioti","year":"2022","journal-title":"Mol Psychiatry"},{"issue":"3","key":"zoi241621r3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/wps.20894","article-title":"Risk and protective factors for mental disorders beyond genetics: an evidence-based atlas.","volume":"20","author":"Arango","year":"2021","journal-title":"World Psychiatry"},{"issue":"4","key":"zoi241621r4","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/dta.2368","article-title":"Potency of ?9-tetrahydrocannabinol and other cannabinoids in cannabis in England in 2016: implications for public health and pharmacology.","volume":"10","author":"Potter","year":"2018","journal-title":"Drug Test Anal"},{"key":"zoi241621r5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-072348","article-title":"Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.","volume":"382","author":"Solmi","year":"2023","journal-title":"BMJ"},{"issue":"11","key":"zoi241621r6","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1001\/jamapsychiatry.2023.3582","article-title":"Transition to schizophrenia spectrum disorder following emergency department visits due to substance use with and without psychosis.","volume":"80","author":"Myran","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"zoi241621r8","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S2215-0366(22)00161-4","article-title":"Association of cannabis potency with mental ill health and addiction: a systematic review.","volume":"9","author":"Petrilli","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"9","key":"zoi241621r10","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1001\/jamapsychiatry.2021.1471","article-title":"Development over time of the population-attributable risk fraction for cannabis use disorder in schizophrenia in Denmark.","volume":"78","author":"Hjorth\u00f8j","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"zoi241621r11","doi-asserted-by":"publisher","year":"2023","journal-title":"JAMA Netw Open","DOI":"10.1001\/jamanetworkopen.2022.52689"},{"issue":"3","key":"zoi241621r12","first-page":"208","article-title":"A framework for the study of access to medical care.","volume":"9","author":"Aday","year":"1974","journal-title":"Health Serv Res"},{"issue":"1","key":"zoi241621r13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.drugpo.2014.09.007","article-title":"Medical marijuana programs: implications for cannabis control policy\u2014observations from Canada.","volume":"26","author":"Fischer","year":"2015","journal-title":"Int J Drug Policy"},{"key":"zoi241621r14","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.addbeh.2018.12.001","article-title":"Retail price and availability of illicit cannabis in Canada.","volume":"90","author":"Mahamad","year":"2019","journal-title":"Addict Behav"},{"key":"zoi241621r17","doi-asserted-by":"publisher","DOI":"10.1111\/dar.13351","article-title":"How has access to legal cannabis changed over time? an analysis of the cannabis retail market in Canada two years following the legalization of recreational cannabis.","year":"2022","journal-title":"Drug Alcohol Rev"},{"issue":"5","key":"zoi241621r18","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/dar.13650","article-title":"Access to legal cannabis market in Canada over the four?years following non-medical cannabis legalisation.","volume":"42","author":"Myran","year":"2023","journal-title":"Drug Alcohol Rev"},{"key":"zoi241621r19","doi-asserted-by":"publisher","first-page":"k757","DOI":"10.1136\/bmj.k757","article-title":"Population attributable fraction.","volume":"360","author":"Mansournia","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"zoi241621r20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2105\/AJPH.88.1.15","article-title":"Use and misuse of population attributable fractions.","volume":"88","author":"Rockhill","year":"1998","journal-title":"Am J Public Health"},{"issue":"7","key":"zoi241621r24","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1111\/add.15834","article-title":"The association between recreational cannabis legalization, commercialization and cannabis-attributable emergency department visits in Ontario, Canada: an interrupted time-series analysis.","volume":"117","author":"Myran","year":"2022","journal-title":"Addiction"},{"issue":"8","key":"zoi241621r25","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1177\/070674371506000805","article-title":"Validation of a Population-Based Algorithm to Detect Chronic Psychotic Illness.","volume":"60","author":"Kurdyak","year":"2015","journal-title":"Can J Psychiatry"},{"issue":"6","key":"zoi241621r26","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00737-018-0847-9","article-title":"Sex and gender differences in schizophrenic psychoses-a critical review.","volume":"21","author":"Riecher-R\u00f6ssler","year":"2018","journal-title":"Arch Womens Ment Health"},{"key":"zoi241621r27","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/916198","article-title":"Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review.","volume":"2012","author":"Ochoa","year":"2012","journal-title":"Schizophr Res Treatment"},{"issue":"10","key":"zoi241621r29","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1038\/s41380-023-02185-x","article-title":"Association between non-medical cannabis legalization and emergency department visits for cannabis-induced psychosis.","volume":"28","author":"Myran","year":"2023","journal-title":"Mol Psychiatry"},{"issue":"15","key":"zoi241621r30","doi-asserted-by":"publisher","first-page":"7322","DOI":"10.1017\/S0033291723000880","article-title":"Association between cannabis use disorder and schizophrenia stronger in young males than in females.","volume":"53","author":"Hjorth\u00f8j","year":"2023","journal-title":"Psychol Med"},{"issue":"4","key":"zoi241621r31","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1001\/jamapsychiatry.2023.0019","article-title":"State cannabis legalization and cannabis use disorder in the US Veterans Health Administration, 2005 to 2019.","volume":"80","author":"Hasin","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"zoi241621r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.109765","article-title":"Cannabis legalization and cannabis use, daily cannabis use and cannabis-related problems among adults in Ontario, Canada (2001-2019).","volume":"244","author":"Imtiaz","year":"2023","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"zoi241621r33","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/dar.13546","article-title":"Changes in health harms due to cannabis following legalisation of non-medical cannabis in Canada in context of cannabis commercialisation: a scoping review.","volume":"42","author":"Myran","year":"2023","journal-title":"Drug Alcohol Rev"},{"key":"zoi241621r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2024.100708","article-title":"The association between physical availability of cannabis retail outlets and frequent cannabis use and related health harms: a systematic review.","volume":"32","author":"Cantor","year":"2024","journal-title":"Lancet Reg Health Am"},{"key":"zoi241621r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104285","article-title":"Impact of non-medical cannabis legalization with market restrictions on health service use and incident cases of psychotic disorder in Ontario, Canada.","volume":"123","author":"Anderson","year":"2024","journal-title":"Int J Drug Policy"},{"issue":"5","key":"zoi241621r36","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1001\/jamapsychiatry.2020.3564","article-title":"Use of genetically informed methods to clarify the nature of the association between cannabis use and risk for schizophrenia.","volume":"78","author":"Gillespie","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"zoi241621r37","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/wps.20629","article-title":"Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study.","volume":"18","author":"Guloksuz","year":"2019","journal-title":"World Psychiatry"},{"key":"zoi241621r7","volume-title":"The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research","author":"National Academies of Sciences, Engineering, and Medicine","year":"2017"},{"key":"zoi241621r9","unstructured":"United Nations Office on Drugs and Crime. World drug report 2022. Accessed July 9, 2024. https:\/\/www.unodc.org\/unodc\/en\/data-and-analysis\/world-drug-report-2022.html"},{"key":"zoi241621r15","unstructured":"Task Force on Cannabis Legalization and Regulation. A framework for the legalization and regulation of cannabis in Canada. November 30, 2016. Accessed July 9, 2024. https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-medication\/cannabis\/laws-regulations\/task-force-cannabis-legalization-regulation\/framework-legalization-regulation-cannabis-in-canada.html"},{"key":"zoi241621r16","unstructured":"Parliament of Canada. Cannabis Act (S.C. 2018, c. 16). 2018. Accessed July 9, 2024. https:\/\/laws-lois.justice.gc.ca\/eng\/acts\/c-24.5\/"},{"key":"zoi241621r21","unstructured":"OSF Registries. Association between cannabis liberalization, first-presentation ED visits due to cannabis and subsequent transition to schizophrenia. Updated January 14, 2024. Accessed December 11, 2024. https:\/\/osf.io\/sjt7v"},{"key":"zoi241621r22","unstructured":"Ministry of Health and Long-Term Care. Early Psychosis Intervention program standards. March 31, 2011. Accessed July 9, 2024. https:\/\/www.nasmhpd.org\/sites\/default\/files\/epi_program_standards.pdf"},{"key":"zoi241621r23","unstructured":"ICES. Mental health and addictions system performance in Ontario: 2021 scorecard: technical appendix. 2021. Accessed October 25, 2023. https:\/\/www.ices.on.ca\/publications\/research-reports\/mental-health-and-addictions-system-performance-in-ontario-2021-scorecard\/"},{"key":"zoi241621r28","unstructured":"Centre for Addiction and Mental Health (CAMH). CAMH monitor. Accessed November 8, 2023. https:\/\/www.camh.ca\/en\/science-and-research\/institutes-and-centres\/institute-for-mental-health-policy-research\/camh-monitor"},{"key":"zoi241621r38","unstructured":"Nigatu? YT, Hamilton? HA. CAMH Monitor eReport 2023: substance use, mental health and well-being among Ontario adults, 1977-2023. Centre for Addiction and Mental Health (CAMH). Accessed July 9, 2024. https:\/\/www.drugsandalcohol.ie\/40519\/1\/CAMH_Monitor_2023_full_report.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2829840\/myran_2025_oi_241621_1738013011.45172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T11:07:38Z","timestamp":1738667258000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2829840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.57868","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]}}}